Revvity, Inc.

Revvity, Inc. is a healthcare diagnostics and research company that provides solutions for disease detection, screening, and laboratory analysis. The company operates through two segments: Diagnostics and Life Sciences. Its product portfolio includes immunoassay analyzers, molecular diagnostics platforms, genetic screening tools, and reagents used in clinical and research laboratories.

Revenue is generated primarily from the sale of instruments, consumables, and services. The Diagnostics segment contributes the majority of revenue, driven by newborn screening, reproductive health, and infectious disease testing. The Life Sciences segment focuses on research tools for drug discovery and cellular analysis. Recurring revenue from consumables and service contracts provides a stable base.

Revvity competes in the highly regulated diagnostics and research industry, alongside players like Thermo Fisher Scientific, Danaher, and Abbott. The company differentiates through specialized offerings in newborn screening and genetic testing. With a market cap of ~$11B and EV/EBITDA of 15.2, it is positioned as a mid-cap player with moderate growth (revenue up 7% YoY) but declining earnings.

Customers include hospitals, clinical laboratories, academic institutions, and pharmaceutical companies. Geographically, revenue is diversified: approximately 45% from the Americas, 30% from Europe, and 25% from Asia-Pacific. The company has a strong presence in developed markets but is expanding in emerging regions.

An auto-generated descriptive profile based on company data, for informational purposes only.